FDA recommends nivolumab–ipilimumab for inoperable mesothelioma
medwireNews: The US FDA has approved nivolumab plus ipilimumab as a first-line treatment for unresectable malignant pleural mesothelioma.
The decision follows the CheckMate 743 trial results showing a significant improvement in overall survival with the combination compared with cisplatin or carboplatin plus pemetrexed chemotherapy.
The most common adverse events reported by trial participants include fatigue, musculoskeletal pain, rash, dyspnea, gastrointestinal symptoms, cough, and pruritus.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group